Evofem Biosciences Stock Fundamentals
| EVFMDelisted Stock | USD 0.05 0.0001 0.21% |
Evofem Biosciences fundamentals help investors to digest information that contributes to Evofem Biosciences' financial success or failures. It also enables traders to predict the movement of Evofem OTC Stock. The fundamental analysis module provides a way to measure Evofem Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Evofem Biosciences otc stock.
Evofem |
Evofem Biosciences OTC Stock Current Valuation Analysis
Evofem Biosciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Evofem Biosciences Current Valuation | 112.69 M |
Most of Evofem Biosciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evofem Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Evofem Biosciences has a Current Valuation of 112.69 M. This is 99.22% lower than that of the Pharmaceuticals sector and 97.57% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.32% higher than that of the company.
Evofem Biosciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Evofem Biosciences's current stock value. Our valuation model uses many indicators to compare Evofem Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Evofem Biosciences competition to find correlations between indicators driving Evofem Biosciences's intrinsic value. More Info.Evofem Biosciences is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Evofem Biosciences by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Evofem Biosciences' OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Evofem Biosciences' earnings, one of the primary drivers of an investment's value.Evofem Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evofem Biosciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Evofem Biosciences could also be used in its relative valuation, which is a method of valuing Evofem Biosciences by comparing valuation metrics of similar companies.Evofem Biosciences is currently under evaluation in current valuation category among related companies.
Evofem Fundamentals
| Return On Equity | -3.87 | ||||
| Return On Asset | -1.25 | ||||
| Operating Margin | (5.41) % | ||||
| Current Valuation | 112.69 M | ||||
| Shares Outstanding | 121.22 M | ||||
| Shares Owned By Insiders | 0.28 % | ||||
| Shares Owned By Institutions | 0.57 % | ||||
| Number Of Shares Shorted | 8.68 M | ||||
| Price To Earning | (1.26) X | ||||
| Price To Book | 8.37 X | ||||
| Price To Sales | 0.42 X | ||||
| Revenue | 8.24 M | ||||
| Gross Profit | 4.19 M | ||||
| EBITDA | (204.14 M) | ||||
| Net Income | (205.19 M) | ||||
| Cash And Equivalents | 19.89 M | ||||
| Cash Per Share | 0.23 X | ||||
| Total Debt | 125.74 M | ||||
| Debt To Equity | 8.72 % | ||||
| Current Ratio | 0.16 X | ||||
| Book Value Per Share | (0.77) X | ||||
| Cash Flow From Operations | (146.67 M) | ||||
| Short Ratio | 0.19 X | ||||
| Earnings Per Share | (19.01) X | ||||
| Target Price | 2.9 | ||||
| Number Of Employees | 119 | ||||
| Beta | -1.25 | ||||
| Market Capitalization | 6.41 M | ||||
| Total Asset | 42.51 M | ||||
| Retained Earnings | (526.68 M) | ||||
| Working Capital | 3.78 M | ||||
| Current Asset | 16.39 M | ||||
| Current Liabilities | 12.61 M | ||||
| Z Score | -30.0 | ||||
| Net Asset | 42.51 M |
About Evofem Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evofem Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evofem Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evofem Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in womens sexual and reproductive health. Evofem Biosciences, Inc. is headquartered in San Diego, California. Evofem Biosciences operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 119 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Evofem Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Evofem Biosciences' short interest history, or implied volatility extrapolated from Evofem Biosciences options trading.
Pair Trading with Evofem Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evofem Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evofem Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Evofem OTC Stock
| 0.68 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
Moving against Evofem OTC Stock
| 0.81 | VERU | Veru Inc Financial Report 9th of May 2024 | PairCorr |
| 0.77 | YS | YS Biopharma | PairCorr |
| 0.71 | DOMH | Dominari Holdings | PairCorr |
| 0.56 | VCEL | Vericel Corp Ord Financial Report 8th of May 2024 | PairCorr |
| 0.51 | DNTH | Dianthus Therapeutics Symbol Change | PairCorr |
The ability to find closely correlated positions to Evofem Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evofem Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evofem Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evofem Biosciences to buy it.
The correlation of Evofem Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evofem Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evofem Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evofem Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Evofem Biosciences information on this page should be used as a complementary analysis to other Evofem Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Evofem OTC Stock
If you are still planning to invest in Evofem Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Evofem Biosciences' history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Stocks Directory Find actively traded stocks across global markets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |